Current and future therapy for malignant pleural effusion

S. M. Keller

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Several options are available for treatment of malignant pleural effusions in patients with non-small-cell lung cancer. Repeat thoracentesis may be appropriate for the patient with limited survival and a slowly recurrent effusion. Pleurodesis with a sclerosing agent administered via a chest tube is the most widely used therapy, though controversy exists as to which drug produces the best results. Pleuroperitoneal shunting remains an option for those patients whose lung is trapped by tumor. Video-assisted thoracoscopy is likely to change the treatment patterns of malignant pleural effusion. Thoracoscopic pleurectomy can be performed with minimal morbidity. Alternatively, sclerosing agents such as talc can be easily and uniformly introduced into the thoracic cavity under thoracoscopic control. Future therapy is likely to entail a diagnostic thoracentesis followed by a definitive thoracoscopic procedure.

Original languageEnglish (US)
JournalChest
Volume103
Issue number1 SUPPL.
StatePublished - 1992
Externally publishedYes

Fingerprint

Malignant Pleural Effusion
Sclerosing Solutions
Pleurodesis
Talc
Thoracic Cavity
Chest Tubes
Thoracoscopy
Therapeutics
Non-Small Cell Lung Carcinoma
Morbidity
Lung
Survival
Pharmaceutical Preparations
Neoplasms
Thoracentesis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Current and future therapy for malignant pleural effusion. / Keller, S. M.

In: Chest, Vol. 103, No. 1 SUPPL., 1992.

Research output: Contribution to journalArticle

Keller, SM 1992, 'Current and future therapy for malignant pleural effusion', Chest, vol. 103, no. 1 SUPPL..
Keller, S. M. / Current and future therapy for malignant pleural effusion. In: Chest. 1992 ; Vol. 103, No. 1 SUPPL.
@article{76a7d52368be41ba84faeb0d28093cdd,
title = "Current and future therapy for malignant pleural effusion",
abstract = "Several options are available for treatment of malignant pleural effusions in patients with non-small-cell lung cancer. Repeat thoracentesis may be appropriate for the patient with limited survival and a slowly recurrent effusion. Pleurodesis with a sclerosing agent administered via a chest tube is the most widely used therapy, though controversy exists as to which drug produces the best results. Pleuroperitoneal shunting remains an option for those patients whose lung is trapped by tumor. Video-assisted thoracoscopy is likely to change the treatment patterns of malignant pleural effusion. Thoracoscopic pleurectomy can be performed with minimal morbidity. Alternatively, sclerosing agents such as talc can be easily and uniformly introduced into the thoracic cavity under thoracoscopic control. Future therapy is likely to entail a diagnostic thoracentesis followed by a definitive thoracoscopic procedure.",
author = "Keller, {S. M.}",
year = "1992",
language = "English (US)",
volume = "103",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Current and future therapy for malignant pleural effusion

AU - Keller, S. M.

PY - 1992

Y1 - 1992

N2 - Several options are available for treatment of malignant pleural effusions in patients with non-small-cell lung cancer. Repeat thoracentesis may be appropriate for the patient with limited survival and a slowly recurrent effusion. Pleurodesis with a sclerosing agent administered via a chest tube is the most widely used therapy, though controversy exists as to which drug produces the best results. Pleuroperitoneal shunting remains an option for those patients whose lung is trapped by tumor. Video-assisted thoracoscopy is likely to change the treatment patterns of malignant pleural effusion. Thoracoscopic pleurectomy can be performed with minimal morbidity. Alternatively, sclerosing agents such as talc can be easily and uniformly introduced into the thoracic cavity under thoracoscopic control. Future therapy is likely to entail a diagnostic thoracentesis followed by a definitive thoracoscopic procedure.

AB - Several options are available for treatment of malignant pleural effusions in patients with non-small-cell lung cancer. Repeat thoracentesis may be appropriate for the patient with limited survival and a slowly recurrent effusion. Pleurodesis with a sclerosing agent administered via a chest tube is the most widely used therapy, though controversy exists as to which drug produces the best results. Pleuroperitoneal shunting remains an option for those patients whose lung is trapped by tumor. Video-assisted thoracoscopy is likely to change the treatment patterns of malignant pleural effusion. Thoracoscopic pleurectomy can be performed with minimal morbidity. Alternatively, sclerosing agents such as talc can be easily and uniformly introduced into the thoracic cavity under thoracoscopic control. Future therapy is likely to entail a diagnostic thoracentesis followed by a definitive thoracoscopic procedure.

UR - http://www.scopus.com/inward/record.url?scp=0027077699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027077699&partnerID=8YFLogxK

M3 - Article

C2 - 8380136

AN - SCOPUS:0027077699

VL - 103

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1 SUPPL.

ER -